Por favor, use este identificador para citar o enlazar este ítem: http://repositorio.pediatria.gob.mx:8180/handle/20.500.12103/2221
Título : A randomized double-blind comparison of moxifloxacin and doxycycline/metronidazole/ciprofloxacin in the treatment of acute, uncomplicated pelvic inflammatory disease
Creador: Heystek M
Nivel de acceso: Open access
Palabras clave : Enfermedad Aguda - terapia - Adulto
Antiinfecciosos - administración & dosificación - Adulto
Antiinfecciosos - uso terapéutico - Adulto
Compuestos Aza - administración & dosificación - Adulto
Compuestos Aza - uso terapéutico - Adulto
Ciprofloxacino - administración & dosificación - Adulto
Ciprofloxacino - uso terapéutico - Adulto
Método Doble Ciego - Adulto
Doxiciclina - administración & dosificación - Adulto
Doxiciclina - uso terapéutico - Adulto
Esquema de Medicación - Adulto
Quimioterapia Combinada - Adulto
Femenina
Metronidazol - administración & dosificación - Adulto- Adulto
Metronidazol - uso terapéutico - Adulto
Enfermedad Inflamatoria Pélvica - quimioterapia - Adulto
Quinolinas - administración & dosificación - Adulto
Quinolinas - uso terapéutico - Adulto
Acute Disease - therapy - Adult
Anti-Infective Agents - administration & dosage - Adult
Anti-Infective Agents - therapeutic use - Adult
Aza Compounds - administration & dosage - Adult
Aza Compounds - therapeutic use - Adult
Ciprofloxacin - administration & dosage - Adult
Ciprofloxacin - therapeutic use - Adult
Double-Blind Method
Doxycycline - administration & dosage - Adult
Doxycycline - therapeutic use - Adult
Drug Administration Schedule - Adult
Drug Therapy, Combination - Adult
Female
Metronidazole - administration & dosage - Adult
Metronidazole - therapeutic use - Adult
Pelvic Inflammatory Disease - drug therapy - Adult
Quinolines - administration & dosage - Adult
Quinolines - therapeutic use - Adult
ciprofloxacin
doxiciclina
metronidazol
moxifloxacin
enfermedad pélvica inflammatory
ciprofloxacin
doxycycline
metronidazole
moxifloxacin
pelvic inflammatory disease
Descripción : This multicentre, double-blind study was undertaken to demonstrate non-inferiority of once-daily oral moxifloxacin compared with combination therapy in the management of acute, uncomplicated pelvic inflammatory disease (PID). Women aged >or=18 years with PID were randomized to receive moxifloxacin (400 mg once daily) for 14 days or comparator treatment (doxycycline [100 mg twice daily] plus metronidazole [400 mg three times daily] for 14 days, plus one single 500-mg ciprofloxacin dose). Of the 434 valid per protocol (PP) patients, the overall clinical success rates at 2-14 days post-therapy were 96.6% (moxifloxacin) and 98.0% (comparator); moxifloxacin was non-inferior to the comparator regimen both in the PP (95% confidence interval [CI]: -4.5, 1.6) and intent-to-treat (95% CI: -5.8, 6.9) populations. Clinical success rates at 21-35 days post-therapy were 93.8% (166/177; data missing for 47 patients) for moxifloxacin and 91.3% (147/161; data missing for 37 patients) for the comparator. Bacteriological success rates at 2-14 days post-therapy were 92.5% (moxifloxacin) and 88.2% (comparator). Once-daily dosing and proven efficacy suggest that moxifloxacin may be of value in acute, uncomplicated PID
Colaborador(es) u otros Autores: Ross JD
Fecha de publicación : 2009
Tipo de publicación: Artículo
Formato: pdf
Identificador del Recurso : 10.1258/ijsa.2008.008495
Fuente: International Journal of STD & AIDS. 20(10):690-5
URI : http://repositorio.pediatria.gob.mx:8180/handle/20.500.12103/2221
Idioma: eng
Aparece en las colecciones: Artículos

Ficheros en este ítem:
No hay ficheros asociados a este ítem.


Los ítems de DSpace están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.